Automated assessment of advanced motor Parkinson’s disease; a pilot study of the Parkinson’s KinetiGraph as an objective tool for measurement of motor fluctuations
Objective: To evaluate the utility of the Parkinson's KinetiGraph (PKG) as a tool in advanced Parkinson's disease (PD) to determine need for treatment change by…Hemi-stereotypies symptomatic to aneurysm: Differential diagnosis of tardive dyskinesia
Objective: Below we present the case of a hemi-stereotypies symptomatic to aneurysm of the middle cerebral artery presented in mass effect on the subthalamic nucleus…Subcutaneous apomorphine reduces OFF time and dyskinesias and improves quality of life in Parkinson’s disease (PD) – 5-year follow-up of patients in Greece
Objective: To evaluate the long-term efficacy of subcutaneous apomorphine (APO) injection and APO infusion in controlling motor fluctuations and dyskinesias and the impact on quality…Automated Telehealth Diagnostics for Remote Parkinson Monitoring
Objective: To clinically assess and evaluate the impact of automated telehealth diagnostics on patients with Parkinson's disease (PD). Background: A single evaluation in a clinical…Duloxetine, a serotonin and norepinephrine reuptake inhibitor, reduces daily OFF time in Parkinson’s disease
Objective: To evaluate efficacy of duloxetine on motor symptoms in Parkinson's disease (PD) patients with wearing-off in an open label trial. Background: Duloxetine, a serotonin…FBOX07 mutation with juvenile parkinsonism and behavioral disorders
Objective: FBX07 (PARK15) mutations cause juvenile parkinsonism with autosomal ressesive inheritance. Juvenile parkinsonism, pyramidal tract signs and atypical symptoms such as dystonia, chorea, behavioral disturbances,…Self-perception of daily performance in relation to motor performance in advanced Parkinson’s disease – Case studies
Objective: To evaluate Parkinson's disease (PD) patients' perception of their performance of daily living (ADL) in their “ON” and “OF” stages and relate them to…AntiParkinsonian treatment patterns and motor complications among patients with Parkinson´s disease in Estonia
Objective: To evaluate pharmacological treatment patterns in patients with Parkinson´s disease (PD), prevalence of motor complications, and factors associated with them. Background: Levodopa is the…A web resource on levodopa-induced dyskinesia (LID) genetics
Objective: Establish a web resource summarizing literature-based genetic information on levodopa-induced dyskinesia in an easily accessible and consistent way. Background: Levodopa induced dyskinesia (LID) is…Real-life data on the use of levodopa carbidopa intestinal gel in Parkinson’s disease
Objective: To report our institution's initial clinical experience with initiation and management of levodopa carbidopa intestinal gel (LCIG) formulation Duopa®. Background: Carbidopa/levodopa intestinal gel (LCIG)…
- « Previous Page
- 1
- …
- 38
- 39
- 40
- 41
- 42
- …
- 44
- Next Page »